Key Insights

Highlights

Treatment Research

2 treatments under study, led by Caris Chromoseq

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Recruiting1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07680868Recruiting

Caris Chromoseq Data Collection

NCT04103359Not ApplicableTerminatedPrimary

Comparison of Lower-risk MDS Patients With and Without Improvements in Fatigue Following Blood Transfusion Therapy

Showing all 2 trials

Research Network

Common Treatments

  • Caris Chromoseq1
  • Physiological Tests To Measure Fatigue Level1

Active Sponsors

  • Jean Monnet University1
  • Caris Science, Inc.1
  • Centre Hospitalier Universitaire de Saint Etienne1
  • Institut de Cancérologie de la Loire1

Top Investigators

Related Conditions

  • Myelodysplastic Mds Myeloproliferative Mpn Diseases1
  • Acute Myeloid Leukemia Aml1
  • Myeloproliferative Neoplasm1

Activity Timeline